Risk Factors For Hepatitis B Virus Infection Among Adult Nigerians With Clinical Features Of Liver Diseases In A Resource-Constrained Environment Of A Primary Care Clinic In Eastern Nigeria
Science Journal of Clinical Medicine
Volume 2, Issue 3, May 2013, Pages: 98-105
Received: May 22, 2013; Published: Jun. 20, 2013
Views 3187      Downloads 262
Authors
Gabriel Uche Pascal Iloh, Department of Family Medicine, Federal Medical Centre, Umuahia, Abia state, Nigeria
Abali Chuku, Department of Ophthalmology Federal Medical Centre, Umuahia, Abia state, Nigeria
Agwu Nkwa Amadi, Department of Public Health Technology, Federal University of Technology, Owerri, Imo state, Nigeria
Nnadozie Paul Obiegbu, Ministry of Health, Awka, Anambra State, Nigeria and Trainer in Family Medicine program, Federal Medical Centre, Owerri, Nigeria
Article Tools
PDF
Follow on us
Abstract
Background: Hepatitis B virus (HBV) infection is an important contributor to the burden of liver diseases in adult Nigerians and constitutes a threat to socio-economic development in the sub-region. Screening for its risk factors in patients with clinical features of liver diseases is an important primary care challenge that is often neglected. Aim: To determine the risk factors for HBV infection in adult Nigerians with clinical features of liver diseases in a resource-constrained environment of a primary care clinic in Eastern Nigeria. Materials and Methods: A cross sectional study was carried out on 140 adult Nigerians with clinical features of liver diseases at the primary care clinic of a tertiary hospital in Nigeria. Clinical features of liver diseases were based on the presence of some constitutional, hepatic and extra-hepatic features. Hepatitis B surface antigen (HBsAg) was assayed using immunochromatographic method. A pre-tested, structured interviewer-administered questionnaire was used to obtain socio-demographic variables and histories of HBV-related risk factors. Results: The HBV sero-prevalence was 50.7%. The age group 40 – 60 years (P=0.048) and artisans (P=0.019) were significantly infected. The behavioural risk factors significantly associated with HBV infection were histories of unprotected sexual exposures (P=0.001), blood transfusion (P=0.022) and non-hepatitis B vaccination (P=0.030). The most significant predictor of HBV infection was history of unprotected sexual exposures (OR=5.04, P=0.003). Conclusion: Risk factors of HBV infection exist in adult Nigerian patients with clinical features of liver diseases and HBV infection was significantly associated with age, occupation, unprotected sexual exposures, blood transfusion and non-hepatitis B vaccination.
Keywords
Hepatitis B Surface Antigen Sero-Marker, Liver Diseases, Nigeria, Primary Care Clinic, Risk Factors
To cite this article
Gabriel Uche Pascal Iloh, Abali Chuku, Agwu Nkwa Amadi, Nnadozie Paul Obiegbu, Risk Factors For Hepatitis B Virus Infection Among Adult Nigerians With Clinical Features Of Liver Diseases In A Resource-Constrained Environment Of A Primary Care Clinic In Eastern Nigeria, Science Journal of Clinical Medicine. Vol. 2, No. 3, 2013, pp. 98-105. doi: 10.11648/j.sjcm.20130203.17
References
[1]
Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol Rev 2006; 28: 112 – 25.
[2]
Alter MJ. Epidemiology of hepatitis B infection in Europe and worldwide, J. Hepatol. 2003; 39: 64-9.
[3]
Zukerman AJ. More than third of world’s population has been infected with hepatitis B virus [Letter]. BMJ 1999; 318: 1213.
[4]
Emechebe GO, Emodi IJ, Ikefuna AN, Ilechukwu GC, Igwe WC, Ejiofor OS, Ilechukwu CA. Hepatitis B Virus Infection in Nigeria – A Review. Niger Med J 2009; 1: 18 – 22.
[5]
Ola SO. Relief to the scourge of primary hepatocellular carcinoma. Niger J Med 2002; 11: 156-60.
[6]
Das BK, Gayen BK, Aditya S, Chakrovorty SK, Datta PK, Joseph A. Seroprevalence of Hepatitis B, Hepatitis C, and human immunodeficiency virus among healthy voluntary first-time blood donors in Kolkata. Ann Trop Med Public Health 2011; 4: 86-90
[7]
Omata M, Dan Y, Damele B, Plentz R, Rudolph K, Manns M. Clinical features, etiology and survival of hepatocellular carcinoma among different countries. J Gastroenterol. Hepatol 2002; 17(Suppl): 40-9.
[8]
Sakhuja P, Malhotra V, Gondal R, Sarin SK, Gupta R, Thakur V. Histological spectrum of chronic hepatitis in precore mutants and wild type hepatitis B virus infection. Trop Doct 2004; 34: 147–8.
[9]
Hayashi PH, Di Bisceglie AM. The progression of hepatitis B and C infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis. Med Clin North Am 2005; 89: 371-89.
[10]
Ndububa DA, Ojo OS, Adetiloye VA, Durosnmi MA, Olasode BJ, Famurewa OC, et al. Chronic hepatitis in Nigerian patients: A study of 70 biopsy-proven cases. West Afr J Med 2005; 24: 107-11.
[11]
Lesi OA, Kehinde MO, Omilabu SA. Prevalence of the HBeAg in Nigerian patients with chronic liver disease. Niger Qt Hosp Med 2004; 14: 1- 4.
[12]
Sirisena ND, Njoku MO, Idoko JA. Carriage rate of HBsAg in an urban community in Jos, Plateau State. Niger Postgrad Med J 2002; 9: 7-10.
[13]
Jumbo GTA, Egah DZ, Banwat EB. Hepatitis B virus infection in a rural settlement of Northern Nigeria. Niger J Med 2005; 14: 425-8.
[14]
Ejele OA, Ojule AC. Hepatitis B antigenaemia (HBsAg): Risk of occupational exposure in a chemical pathology laboratory in Nigeria. Niger J Clin Pract 2003; 6: 99-101.
[15]
Ola SO, Odaibo GN. Alfa-feto protein, HCV and HBV infections in Nigerian patients with primary hepatocellular carcinoma. Niger Med Pract 2007; 51: 33-5.
[16]
Ogunbiyi JO. Hepatocellular carcinoma in developing world, Semin Oncol 2001; 28:179-87.
[17]
Adeniji KA, Anjorin AS. The pattern of malignant tumors of the Liver in a tertiary health institution in Nigeria. Afr J Med Sci 2004; 33: 27-30.
[18]
Abdulkareem FB, Banjo AAF, Elesha SO, Daramola AO. Histopathological study of liver diseases at the Lagos University Teaching Hospital, Nigeria: 1989-2000. Niger Postgrad Med J 2006; 13: 41-6.
[19]
Baba MM, Ajayi BB, Ekanem LA. Prevalence of HBsAg among patients suspected of liver diseases in a Nigerian hospital. Niger Postgrad Med J 2000; 7: 91- 5.
[20]
Lesi. OA, Kehinde MO, Anomneze EE. Chronic liver disease in Lagos: A clinicopathological study. Niger Postgrad Med J 2004; 11: 91-6.
[21]
Ola SO, Otagbeyo JA, Odaibo GN, Olaleye OD, Olubuyide OI. Serum hepatitis C virus and HBsAg in Nigerian patients with acute icteric hepatitis. West Afr J Med 2002; 21: 215-17.
[22]
Khan WI, Sultana R, Rahman M, Akhter H, Haq JA, Mohsin MA, Khan AK. Viral hepatitis: recent experiences from serological studies in Bangladesh. Asian Pac J allergy Immunol 2000; 18: 99-103.
[23]
Khan M, Haq S, Ahmed N, Matin MA. Etilogy and clinical profile of hepatocellular carcinoma in Bangladesh. Bangladesh Med Res Counc Bull 1997; 23: 16-24.
[24]
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures: A review. J Viral Hepat 2004; 2: 97 – 107.
[25]
Iroezindu MO, Daniyam CA, Isa ES, Okeke EN, Agbaji OO. High-risk behaviour among hepatitis B virus-infected patients in Nigerian tertiary hospital. Jos Journal of Medicine 2012; 6: 8-12.
[26]
Adekanle O, Ndububa DA, Ayodeji OO, Paul-Odo B, Folorunso TA. Sexual transmission of the hepatitis B virus among blood donors in a tertiary hospital in Nigeria. Singapore Med J 2010; 51: 944-47.
[27]
Jimenez AP, El-Din NS, El-Hoseiny M, El-Daly M, Abdel-Hamid M, El-Aidi S, et al. Community transmission of hepatitis B virus in Egypt: results from a case-control study in Greater Cairo. International Journal of Epidemiology 2009; 38: 757-65.
[28]
Sattar H, Islam MN. Hepatitis B virus markers among the prostitutes of Dhaka. Bangladesh Med Res Counc Bull 1996; 22: 8-11.
[29]
Ion-Nedelcu N, Iordachescu C, Gherasim P, Mihailovici R, Dragomirescu C, Dumitrache-Marian R, et al. Prevalence of risk factors and mechanisms of transmission of acute viral hepatitis type B and C in Bucharest municipality: 2001-2008. Bacteriol Virusol Parazitol Epidemiol 2009; 54: 103-8.
[30]
Ibrahim T. Sample size determination. In: Research Methodology and Dissertation writing for Health and Allied Health Professionals. Abuja, Nigeria Cress Global Link Limited; 2009: 70-75.
[31]
Araoye MO. Sample size determination. Research Methodology with Statistics for Health and Social Sciences, Ilorin, Nathadex Publishers, 2004. P.115- 21.
[32]
Omoigberale AI, Airauhi LU. Aspects of the epidemiology of intestinal parasitoses(IP) in children: knowledge, practices and perceptions of mothers. Niger J Clin Pract 2006; 9:109-13.
[33]
Hoofnagle JH. Hepatitis B: preventable and now treatable. New Engl J Med 2006; 354: 1074- 76.
[34]
Ola SO, Jaiyesimi AEA, Olusanya OO. Co-infection of human immunodeficiency virus and hepatitis B virus among Nigerian patients and blood donors at Sagamu. Niger Med J 2005; 46: 64-7.
[35]
Hyams KC. Risk of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1997; 20: 992–1000.
[36]
Sherlock S, Dooley J. Diseases of the Liver and Biliary Sysem. Oxford, Blackwell Publishers 2002. p. 294.
[37]
Glynn AS, Kleinman SH, Schreiber GB, Bush MP, Wright DJ, Smith JW et al. Trends in the incidence and prevalence of major transfusion transmissible viral infection in the USA, JAMA 2000; 284:229-30.
[38]
Iyaniwura CA. Health Promotion in General Medical Practice in Ogun State. Niger Med Pract 2004; 45: 29-32.
[39]
Ola SO, Anomneze EE, Chukwuani CM, Ojo SC, Ndububa DA, Onyekwere B, etal: Interferon alpha–2a (Roferon) in the Management of chronic hepatitis B infection; Results of an open prospective study in Nigerian patients, West Afr J Med 2000; 19: 259-64.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186